HER2 ELISA Kits Market Size, Share, Trends & Forecast
The Her2 Elisa Kits Market is gaining importance as healthcare providers and research organizations seek reliable methods for assessing HER2-related biomarkers. According to WiseGuyReports, the market was valued at USD 700 million in 2024 and is projected to reach USD 1.2 billion by 2035, expanding at a CAGR of 4.4% during 2026–2035.
Diagnostic applications represent a major part of demand because HER2 testing can contribute to cancer characterization and personalized treatment strategies. The diagnostic applications segment was valued at USD 320 million in 2024 and is forecast to reach USD 480 million by 2035. Increasing emphasis on early diagnosis and more precise biomarker measurement is supporting this expansion.
Technological improvements are also influencing the market. Developers are working toward assays with greater sensitivity and specificity, while automation and high-throughput testing can help laboratories improve efficiency and manage larger testing volumes. Quantitative testing is gaining preference as healthcare professionals seek more precise measurements of HER2 levels.
Hospitals are expected to remain leading end users, followed by diagnostic laboratories and research institutions. These organizations use HER2 ELISA technologies across diagnostic, research, and therapeutic-development activities, creating demand for different kit formats and detection approaches.
North America maintains a leading position, with its market estimated at USD 320 million in 2024 and projected to reach USD 490 million by 2035. Asia-Pacific is also expected to show strong potential as healthcare infrastructure, diagnostic investment, and awareness of advanced cancer testing continue to develop.